비교리스트

 카트 문의
시장보고서
상품코드
1355788

울혈성심부전(CHF) 시장 - 성장, 향후 전망, 경쟁 분석(2023-2031년)

Congestive Heart Failure (CHF) Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 119 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

심부전이라고도 알려진 울혈성심부전(CHF)은 심장이 혈액을 효율적으로 펌프질하는 능력이 저하되는 만성 질환입니다. 이 질환은 심장 근육이 약해지거나 손상되어 신체가 필요로 하는 산소를 함유한 혈액을 충분히 공급하지 못하기 때문에 발생합니다. 그 결과 체내 여러 부위에 수분이 축적되어 숨가쁨, 피로감, 다리와 발목의 부종(부종), 신체 활동의 어려움 등의 증상이 나타납니다. 울혈성심부전 치료제 시장은 2023년부터 2031년까지 예측 기간 동안 연평균 14.5%의 성장률을 보일 것으로 예상됩니다. 심장 질환의 확산과 의료 기술의 발전이 결합하여 효과적인 CHF 치료제에 대한 수요가 유지될 것입니다. 규제적 도전은 계속될 것이며, 기업들은 복잡한 승인 절차를 통과해야 합니다. 다양한 환자들의 요구를 충족시키기 위해서는 클래스별, 판매 채널별 시장 세분화가 계속 중요할 것입니다.

심장질환 유병률 증가

CHF 치료제 시장의 주요 촉진요인 중 하나는 전 세계 심장병 유병률의 증가입니다. 세계보건기구(WHO)는 심혈관 질환을 전 세계 사망 원인 1위로 꼽고 있습니다. 울혈성심부전 발병률의 증가는 좌식 생활습관 및 식습관 장애와 같은 요인으로 인해 악화되고 있으며, 효과적인 치료 옵션에 대한 수요가 크게 증가하고 있습니다. 인구의 고령화로 인해 심장 관련 질환의 부담이 증가하여 시장 성장을 더욱 촉진할 것으로 예상됩니다.

의료기술의 진보

CHF 치료 환경은 의료기술의 발전으로 인해 완전히 바뀌었습니다. 약물전달 시스템, 개인 맞춤형 의료 접근법, 새로운 화합물 개발의 혁신은 환자들의 치료 결과를 크게 개선했습니다. 특히, 사쿠비트릴/발사르탄(엔트레스트)의 도입은 박출률이 저하된 심부전 관리에 획기적인 진전을 가져왔습니다. 이러한 발전은 치료 효과를 향상시켰을 뿐만 아니라 의료진과 환자가 이용할 수 있는 치료 옵션을 확대했습니다.

조기 진단과 조기 치료의 중요성

심장 질환의 조기 진단과 적시 치료를 촉진하기 위한 노력은 CHF 치료제 시장에 긍정적인 영향을 미치고 있습니다. 의료 기관과 정부의 심장 건강 및 조기 개입의 이점에 대한 인식 개선 노력은 환자들의 인식 개선으로 이어지고 있습니다. 심부전을 조기에 발견하면 의료진은 질병의 진행을 막고 전반적인 삶의 질을 향상시킬 수 있는 치료 전략을 시행할 수 있습니다. 이러한 노력은 CHF 치료제에 대한 수요를 증가시키고 있습니다.

엄격한 규제 요구 사항

CHF 치료제 시장은 성장하고 있지만, 엄격한 규제 요건으로 인해 어려움을 겪고 있습니다. 신약 개발 및 승인 과정은 복잡하고 시간이 오래 걸리며, FDA 및 EMA와 같은 규제 기관은 신약 후보물질에 대해 엄격한 안전성 및 유효성 기준을 적용하고 있어 개발 기간이 길어지고 비용이 상승하고 있습니다. 이러한 규제 환경을 극복하는 것은 특히 중소 제약사에게 어려운 일이며, 시장 성장의 걸림돌로 작용하고 있습니다.

안지오텐신2 수용체 길항제, 계열별 시장 독식

안지오텐신2수용체 길항제(ARB)가 2022년 가장 높은 매출을 기록했습니다. 안지오텐신2 수용체 길항제는 혈관 수축과 체액 저류를 유발하는 호르몬인 안지오텐신 II의 작용을 억제해 효과를 발휘하는 약물입니다. 이러한 작용을 억제함으로써 ARB는 혈관을 이완시키고, 혈압을 낮추며, 심장의 부담을 줄여주며, 심부전 및 고혈압과 같은 관련 질환을 관리하기 위해 자주 처방되며, ACE 억제제, 베타차단제, 이뇨제 등 다른 약물과 병용하여 심부전 환자의 종합적인 치료를 위해 합니다. 이러한 약물은 증상을 개선하고 심장의 펌프 기능을 향상시켜 전반적으로 더 나은 병리학적 관리에 기여합니다. 안지오텐신2수용체 길항제는 이미 확립된 효과와 광범위한 사용으로 인해 지금까지 CHF 치료제 시장에서 큰 수익을 창출해 왔습니다. 안지오텐신2 수용체 길항제는 심부전 치료의 다양한 측면을 충족시킬 수 있기 때문에 많은 환자들에게 치료 요법의 중요한 구성요소가 되고 있습니다. 그러나 각 약물군이 창출하는 수익은 시장 역학, 가격 책정, 환자 선호도, 새로운 치료 옵션의 출현 등 다양한 요인에 따라 변동될 수 있다는 점을 염두에 두어야 합니다.

병원 약국, 유통 채널별 시장 독식

2022년에는 병원 약국이 가장 높은 매출을 기록했습니다. 병원 내 약국은 입원 환자와 외래 환자 모두에게 의약품을 조제하는 병원 내 의료 시설입니다. 이 약국들은 CHF를 포함한 급성 질환을 앓고 있는 환자들에게 필수 의약품에 대한 즉각적인 접근을 제공하는 중요한 역할을 담당하고 있습니다. 병원 내 약국에서는 심부전 치료제를 포함한 다양한 종류의 의약품을 취급하는 경우가 많으며, 의료 전문가의 감독 하에 환자가 적절한 약물과 용량을 받을 수 있도록 합니다. 중증 심부전이나 그 합병증으로 입원한 환자에게는 직접 정맥주사나 근육주사를 투여하는 경우도 있는데, 병원 내 약국은 이러한 환자들을 위한 약품도 취급합니다.

북미, 세계 리더의 자리를 지킨다

CHF 치료제 시장의 지리적 추세는 지역별로 다른 양상을 보이고 있는데, 아시아태평양이 가장 높은 CAGR을 보이고 있으며, 이는 의료 인프라의 발전, 노인 인구의 증가, 고혈압 및 당뇨병과 같은 위험 요인의 확산 등의 복합적인 요인이 작용한 것으로 분석됩니다. 북미는 잘 구축된 의료 시스템, 높은 의료비, 연구개발 활동에 대한 집중적인 노력으로 인해 지속적으로 가장 높은 매출 점유율을 유지하고 있습니다.

경쟁사 동향 및 주요 전략

경쟁이 치열한 CHF 치료제 시장에서 주요 기업들은 시장에서의 입지를 유지하고 혁신을 추진하기 위해 다양한 전략을 채택하고 있으며, Bayer AG, Novartis AG, Merck &, Inc. Myers Squibb Company, Amgen Inc, Boehringer Ingelheim International Gmbh, Pfizer, Inc, Johnson & Johnson Services, Inc, Otsuka Pharmaceutical Co. and Company, Novo Nordiska/S와 같은 주목할 만한 기업들은 포트폴리오를 확장하고 시장 도달 범위를 강화하기 위해 합병, 인수, 제휴 및 제품 출시를 추진하고 있습니다. 또한, 이들 기업은 정밀 치료, 개인화된 의료 접근법, 환자 결과 개선에 초점을 맞춘 연구개발에 많은 투자를 하고 있습니다.

목차

제1장 서문

  • 보고서 내용
    • 보고서 목적
    • 대상자
    • 주요 제공 상품
  • 시장 세분화
  • 조사 방법
    • 단계Ⅰ - 2차 조사
    • 단계Ⅱ - 1차 조사
    • 단계Ⅲ - 전문가 패널 리뷰
    • 가정
    • 채용한 접근법

제2장 주요 요약

제3장 울혈성심부전(CHF) 시장 : 경쟁 분석

  • 주요 벤더의 시장에서의 포지셔닝
  • 벤더가 채용하는 전략
  • 주요 산업 전략
  • 계층 분석 : 2022 vs 2031

제4장 울혈성심부전(CHF) 시장 : 거시적 분석과 시장 역학

  • 서론
  • 세계의 울혈성심부전(CHF) 시장 금액 2021-2031
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • See-Saw 분석

제5장 울혈성심부전(CHF) 시장 : 약제 클래스별 2021-2031

  • 시장 개요
  • 성장·매출 분석 : 2022 vs 2031
  • 시장 세분화
    • ACE 억제제
    • 안지오텐신 2 수용체 차단제
    • 베타 차단제
    • 이뇨제
    • 알도스테론 길항제
    • 변력제
    • 기타

제6장 울혈성심부전(CHF) 시장 : 유통 채널별 2021-2031

  • 시장 개요
  • 성장·매출 분석 : 2022 vs 2031
  • 시장 세분화
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제7장 북미의 울혈성심부전(CHF) 시장 2021-2031

  • 시장 개요
  • 울혈성심부전(CHF) 시장 : 약제 클래스별 2021-2031
  • 울혈성심부전(CHF) 시장 : 유통 채널별 2021-2031
  • 울혈성심부전(CHF) 시장 : 지역별 2021-2031
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제8장 영국과 유럽연합의 울혈성심부전(CHF) 시장 2021-2031

  • 시장 개요
  • 울혈성심부전(CHF) 시장 : 약제 클래스별 2021-2031
  • 울혈성심부전(CHF) 시장 : 유통 채널별 2021-2031
  • 울혈성심부전(CHF) 시장 : 지역별 2021-2031
    • 영국과 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제9장 아시아태평양의 울혈성심부전(CHF) 시장 2021-2031

  • 시장 개요
  • 울혈성심부전(CHF) 시장 : 약제 클래스별 2021-2031
  • 울혈성심부전(CHF) 시장 : 유통 채널별 2021-2031
  • 울혈성심부전(CHF) 시장 : 지역별 2021-2031
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제10장 라틴아메리카의 울혈성심부전(CHF) 시장 2021-2031

  • 시장 개요
  • 울혈성심부전(CHF) 시장 : 약제 클래스별 2021-2031
  • 울혈성심부전(CHF) 시장 : 유통 채널별 2021-2031
  • 울혈성심부전(CHF) 시장 : 지역별 2021-2031
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제11장 중동 및 아프리카의 울혈성심부전(CHF) 시장 2021-2031

  • 시장 개요
  • 울혈성심부전(CHF) 시장 : 약제 클래스별 2021-2031
  • 울혈성심부전(CHF) 시장 : 유통 채널별 2021-2031
  • 울혈성심부전(CHF) 시장 : 지역별 2021-2031
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제12장 기업 개요

  • Bayer AGNovartis AG
  • Merck & co. Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • BoehringerIngelheiminternationalGmbh
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Novo Nordiska/S
  • 기타 주요 기업
ksm 23.10.30

Congestive heart failure (CHF), also known as heart failure, is a chronic medical condition in which the heart's ability to pump blood efficiently is compromised. This condition occurs when the heart muscles become weakened or damaged, leading to an inadequate supply of oxygenated blood to meet the body's needs. As a result, fluid may accumulate in various parts of the body, causing symptoms such as shortness of breath, fatigue, swelling in the legs and ankles (edema), and difficulty performing physical activities. The congestive heart failure drug market is expected to grow at a CAGR of 14.5% during the forecast period of 2023 to 2031. The prevalence of heart diseases, coupled with ongoing advancements in medical technology, will sustain the demand for effective CHF treatments. Regulatory challenges will persist, requiring companies to navigate complex approval processes. Market segmentation by class and distribution channels will remain instrumental in catering to diverse patient needs.

Rising Prevalence of Heart Diseases

One of the primary drivers of the CHF drugs market is the escalating prevalence of heart diseases worldwide. The World Health Organization (WHO) has identified cardiovascular diseases as the leading cause of mortality globally. The growing incidence of congestive heart failure, exacerbated by factors like sedentary lifestyles and poor dietary habits, has substantially increased the demand for effective treatment options. As the population ages, the burden of heart-related ailments is projected to rise, further fueling the market's growth.

Advancements in Medical Technology

The landscape of CHF treatment has been revolutionized by advancements in medical technology. Innovations in drug delivery systems, personalized medicine approaches, and the development of novel drug compounds have significantly improved patient outcomes. Notably, the introduction of sacubitril/valsartan (Entresto) has marked a breakthrough in managing heart failure with reduced ejection fraction. Such advancements have not only enhanced the efficacy of treatments but have also expanded the treatment options available to healthcare providers and patients.

Focus on Early Diagnosis and Treatment

Efforts to promote early diagnosis and timely treatment of heart conditions have had a positive impact on the CHF drugs market. Initiatives by healthcare organizations and governments to raise awareness about heart health and the benefits of early intervention have led to increased patient awareness. By identifying heart failure in its early stages, medical professionals can implement treatment strategies that prevent disease progression and improve overall quality of life. These efforts have collectively driven the demand for CHF drugs.

Stringent Regulatory Requirements

While the CHF drugs market has experienced growth, it has also encountered challenges posed by stringent regulatory requirements. The process of developing and gaining approval for new drugs is complex and time-consuming. Regulatory agencies such as the FDA and EMA impose rigorous safety and efficacy standards on new drug candidates, leading to prolonged development timelines and elevated costs. Navigating the regulatory landscape can be particularly challenging for smaller pharmaceutical companies, acting as a restraint on market growth.

Angiotensin 2 Receptor Blockers Dominated Market by Class

In 2022, Angiotensin 2 Receptor Blockers (ARBs) held highest revenue. Angiotensin 2 Receptor Blockers are a class of medications that work by blocking the effects of the hormone angiotensin II, which can lead to blood vessel constriction and fluid retention. By blocking these effects, ARBs help relax blood vessels, reduce blood pressure, and decrease the workload on the heart. ARBs are commonly prescribed to manage CHF and related conditions, such as hypertension. They are often used in combination with other medications, such as ACE inhibitors, beta blockers, and diuretics, to provide comprehensive treatment for heart failure patients. These medications can help improve symptoms, enhance the heart's pumping efficiency, and overall contribute to better management of the condition. Due to their established efficacy and widespread use, Angiotensin 2 Receptor Blockers have historically generated substantial revenue in the CHF drugs market. Their ability to address multiple aspects of heart failure management makes them a critical component of treatment regimens for many patients. However, it's important to note that the revenue generated by each drug class can vary based on factors such as market dynamics, pricing, patient preferences, and the emergence of newer treatment options.

Hospital Pharmacies Dominates Market by Distribution Channel

In 2022, Hospital Pharmacies held highest revenue. Hospital Pharmacies are healthcare facilities within hospitals that dispense medications to both inpatients and outpatients. These pharmacies play a crucial role in providing immediate access to essential medications for patients with acute conditions, including CHF. Hospital Pharmacies often have a wide range of medications available, including those for treating heart failure, and they ensure that patients receive the right medications and dosages under the supervision of healthcare professionals. Patients hospitalized due to severe CHF or related complications may have their medications administered directly through intravenous (IV) or intramuscular (IM) injections, which are facilitated by Hospital Pharmacies.

North America Remains as the Global Leader

The geographic trends in the CHF drugs market reveal varying patterns across regions. The region with the highest CAGR is Asia-Pacific, driven by a combination of factors such as increasing healthcare infrastructure development, a rising geriatric population, and the prevalence of risk factors like hypertension and diabetes. North America has consistently held the highest revenue share, attributed to its well-established healthcare systems, significant healthcare expenditure, and a robust focus on research and development activities.

Competitive Trends and Key Strategies

In the fiercely Competitive Landscape of the CHF drugs market, leading players have adopted diverse strategies to maintain their market presence and drive innovation. Notable players like Bayer AG,Novartis AG, Merck & co., Inc., Astrazeneca, Bristol-Myers Squibb Company, Amgen Inc., BoehringerIngelheiminternationalGmbh, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, and Novo Nordiska/S have pursued mergers, acquisitions, collaborations, and product launches to expand their portfolios and enhance their market reach. These companies are also investing heavily in research and development endeavors, focusing on precision therapies, personalized medicine approaches, and improved patient outcomes.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofCongestive Heart Failure (CHF) market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Congestive Heart Failure (CHF) market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Congestive Heart Failure (CHF) market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Congestive Heart Failure (CHF) market?
  • Which is the largest regional market for Congestive Heart Failure (CHF) market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Congestive Heart Failure (CHF) market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Congestive Heart Failure (CHF) market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Congestive Heart Failure (CHF) Market
  • 2.2. Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 (US$ Million)
  • 2.3. Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 (US$ Million)
  • 2.4. Global Congestive Heart Failure (CHF) Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Congestive Heart Failure (CHF) Market: Competitive Analysis

  • 3.1. Market Positioning of Key Congestive Heart Failure (CHF) Market Vendors
  • 3.2. Strategies Adopted by Congestive Heart Failure (CHF) Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Congestive Heart Failure (CHF) Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Congestive Heart Failure (CHF) Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. ACE Inhibitors
    • 5.3.2. Angiotensin 2 Receptor Blockers
    • 5.3.3. Beta Blockers
    • 5.3.4. Diuretics
    • 5.3.5. Aldosterone Antagonists
    • 5.3.6. Inotropes
    • 5.3.7. Others

6. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies

7. North America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 7.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 7.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

8. UK and European Union Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 8.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 8.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

9. Asia Pacific Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 9.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 9.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

10. Latin America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 10.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 10.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

11. Middle East and Africa Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 11.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 11.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Bayer AG,Novartis AG
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Merck & co., Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Astrazeneca
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bristol-Myers Squibb Company
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Amgen Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. BoehringerIngelheiminternationalGmbh
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Pfizer, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Otsuka Pharmaceutical Co., Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Eli Lilly and Company
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Novo Nordiska/S
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Other Notable Players
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제